CEFODIZIME (THR-221) IN OBSTETRICS AND GYNECOLOGY

We performed a basic and clinical study on cefodizime (THR-221), an injectable cephem, to evaluate its usefulness in obstetric and gynecological infections. Favorable distribution to the uterus and adnexa was shown after administration of the drug at 1g, and the levels in these tissues were enough t...

Full description

Saved in:
Bibliographic Details
Published inCHEMOTHERAPY Vol. 36; no. Supplement5; pp. 927 - 931
Main Authors MATSUDA, SEIJI, SUZUKI, MASAAKI, MIYAZAKI, RYOICHIRO, OH, KINKI
Format Journal Article
LanguageJapanese
Published Japanese Society of Chemotherapy 1988
Online AccessGet full text

Cover

More Information
Summary:We performed a basic and clinical study on cefodizime (THR-221), an injectable cephem, to evaluate its usefulness in obstetric and gynecological infections. Favorable distribution to the uterus and adnexa was shown after administration of the drug at 1g, and the levels in these tissues were enough to cover main pathogens in the treatment of various obstetric and gynecological infections. Two grams per i. v. injection (or drip infusion) was given to a total of 14 patients with pelvic infections (intrauterine infection, pyometra, adnexitis, etc.) and puerperal endometritis, and the efficacy rate was 85.7%(12 patients). Bacteriologically, isolates included various anaerobes, Streptococcus, aerobic Gram-negative bacilli, etc. Three strains were eliminated and 2 strains (E. cloacae) replaced. No notable adverse reactions occurred and no abnormal laboratory finding were detected.
ISSN:0009-3165
1884-5894
DOI:10.11250/chemotherapy1953.36.Supplement5_927